Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian G Feagan

Showing results (231-240 of 464) with videos related to

Pageof 47
Sort By:
Journal of Crohn'S & Colitis|July 20, 2024
Re-evaluating Methods for Assessing Differences in Response in Ileal vs Colonic Crohn's Disease: A Post-hoc Analysis of the FITZROY TrialChristopher Ma, Brian G Feagan, Zhongya Wang, et al.
Expert Opinion on Drug Safety|July 21, 2022
Safety and tolerability of spesolimab in patients with ulcerative colitisMarc Ferrante, Peter M Irving, Christian P Selinger, et al.
Gastroenterology|September 1, 2014
Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitisOmoniyi J Adedokun, William J Sandborn, Brian G Feagan, et al.
Clinical and Translational Gastroenterology|April 29, 2016
Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT-SC Maintenance Study Extension Through 1 YearPeter R Gibson, Brian G Feagan, William J Sandborn, et al.
The Cochrane Database of Systematic Reviews|January 17, 2018
Endoscopic scoring indices for evaluation of disease activity in ulcerative colitisNadia Mohammed Vashist, Mark Samaan, Mahmoud H Mosli, et al.
Alimentary Pharmacology & Therapeutics|November 23, 2019
Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitisParambir S Dulai, Siddharth Singh, Vipul Jairath, et al.
Gastroenterology|January 30, 2007
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitisGeert D'Haens, William J Sandborn, Brian G Feagan, et al.
Gastroenterology|September 22, 2009
Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitisWilliam J Sandborn, Jaroslaw Regula, Brian G Feagan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 22, 2023
Effects of Mirikizumab on Histologic Resolution of Crohn's Disease in a Randomized Controlled Phase 2 TrialFernando Magro, Marijana Protic, Gert De Hertogh, et al.
Scientific Reports|September 15, 2021
Meta-analysis of gene expression disease signatures in colonic biopsy tissue from patients with ulcerative colitisBryan Linggi, Vipul Jairath, Guangyong Zou, et al.
Pageof 47

Showing results (231-240 of 464) with videos related to

Sort By:
Pageof 47
Journal of Crohn'S & Colitis|July 20, 2024
Re-evaluating Methods for Assessing Differences in Response in Ileal vs Colonic Crohn's Disease: A Post-hoc Analysis of the FITZROY TrialChristopher Ma, Brian G Feagan, Zhongya Wang, et al.
Expert Opinion on Drug Safety|July 21, 2022
Safety and tolerability of spesolimab in patients with ulcerative colitisMarc Ferrante, Peter M Irving, Christian P Selinger, et al.
Gastroenterology|September 1, 2014
Association between serum concentration of infliximab and efficacy in adult patients with ulcerative colitisOmoniyi J Adedokun, William J Sandborn, Brian G Feagan, et al.
Clinical and Translational Gastroenterology|April 29, 2016
Maintenance of Efficacy and Continuing Safety of Golimumab for Active Ulcerative Colitis: PURSUIT-SC Maintenance Study Extension Through 1 YearPeter R Gibson, Brian G Feagan, William J Sandborn, et al.
The Cochrane Database of Systematic Reviews|January 17, 2018
Endoscopic scoring indices for evaluation of disease activity in ulcerative colitisNadia Mohammed Vashist, Mark Samaan, Mahmoud H Mosli, et al.
Alimentary Pharmacology & Therapeutics|November 23, 2019
Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitisParambir S Dulai, Siddharth Singh, Vipul Jairath, et al.
Gastroenterology|January 30, 2007
A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitisGeert D'Haens, William J Sandborn, Brian G Feagan, et al.
Gastroenterology|September 22, 2009
Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitisWilliam J Sandborn, Jaroslaw Regula, Brian G Feagan, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|November 22, 2023
Effects of Mirikizumab on Histologic Resolution of Crohn's Disease in a Randomized Controlled Phase 2 TrialFernando Magro, Marijana Protic, Gert De Hertogh, et al.
Scientific Reports|September 15, 2021
Meta-analysis of gene expression disease signatures in colonic biopsy tissue from patients with ulcerative colitisBryan Linggi, Vipul Jairath, Guangyong Zou, et al.
Pageof 47